PRADA: Anti-Breast Cancer Therapy With Candesartan May Reduce a LVEF Decline

In breast cancer patients, candesartan cilexetil in addition to adjuvant anti-cancer therapy may "provide protection" against a decline in left ventricular ejection fraction (LVEF), according to results from the PRADA trial presented Nov. 11 during AHA 2015 in Orlando.

The study looked at 126 women ages 18-70 years with early breast cancer who were given metoprolol succinate (100 mg daily) and/or candesartan cilexetil (32 mg daily) or placebo in addition to adjuvant anti-cancer therapy. The duration of therapy ranged from 10 to 61 weeks.

Results showed that the overall decline in LVEF was 2.6 percentage points in the placebo group, and 0.8 percentage points in the candesartan group. However, there was no observed effect of metoprolol on a change in LVEF.

The investigators explain that moving forward, "if a sustained, long-term effect of early angiotensin inhibition can be confirmed, preventive therapy may be indicated as standard care."

"These results, while encouraging, must be viewed as preliminary," said Kim A. Eagle, MD, MACC, editor-in-chief of

Clinical Topics: Novel Agents

Keywords: AHA Annual Scientific Sessions, Adjuvants, Pharmaceutic, Angiotensins, Benzimidazoles, Biphenyl Compounds, Breast Neoplasms, Metoprolol, Tetrazoles, Stroke Volume

< Back to Listings